| Literature DB >> 35756979 |
Lauren Beresford1, Todd Norwood1.
Abstract
Objective: To examine the effect of digital physical therapy (PT) delivered by mobile application (app) on reducing pain and improving function for people with a variety of musculoskeletal conditions. Design: An observational, longitudinal, retrospective study using survey data collected pre- and postdigital PT to estimate multilevel models with random intercepts for patient episodes. Setting: Privately insured employees participating in app-based PT as an employer health care benefit. Participants: The study sample included 814 participants (N=814) 18 years or older who completed their digital PT program with reported final clinical outcomes between February 2019 (program launch) through December 2020. Mean age of the sample at baseline was 40.9±11.89 years, 47.5% were female, 21% sought care for lower back pain, 16% for shoulders, 15% for knees, and 13% for neck. Interventions: Digital PT consisted of a synchronous video evaluation with a physical therapist followed by a course of PT delivered through a mobile app. Main Outcome Measures: Pain was measured by the visual analog scale from 0 "no pain" to 10 "worst pain imaginable" and physical function by the Patient-Specific Functional Scale on a scale from 0 "completely unable to perform" to 10 "able to perform normally."Entities:
Keywords: Delivery of health care; ICC, interclass correlation coefficient; Mobile applications; OSPRO-ROS, Optimal Screening for Prediction of Referral and Outcome Review of Systems; PCP, primary care provider; PSFS, Patient-Specific Functional Scale; PT, physical therapy; Physical therapy specialty; Rehabilitation; Telerehabilitation; VAS, Visual Analog Scale; app, application
Year: 2022 PMID: 35756979 PMCID: PMC9214340 DOI: 10.1016/j.arrct.2022.100186
Source DB: PubMed Journal: Arch Rehabil Res Clin Transl ISSN: 2590-1095
Descriptive statistics for intervention (N=814)
| Patient–Provider Interactions | Mean | SD | Min | Max |
|---|---|---|---|---|
| No. of follow-up visits | 2.11 | 2.99 | 0 | 30 |
| Unique days therapist messaged/wk | 1.81 | 1.06 | 0 | 7 |
| Unique days participant messaged/wk | 10.08 | 7.97 | 0 | 67 |
| Engagement | ||||
| No. of workouts/wk | 2.78 | 2.19 | 0 | 17 |
| No. of in-app activities/wk | 3.72 | 2.20 | 0 | 16 |
| Wk in program | 9.09 | 5.36 | 2 | 52 |
Fig 1Study participation flow diagram.
Descriptive statistics for sample participants (N=814)
| Demographics | Count | Mean | SD | Min | Max |
|---|---|---|---|---|---|
| Female | 387 | 0.48 | 0.50 | 0 | 1 |
| Age | 814 | 40.85 | 11.89 | 18 | 74 |
| Age ≥50 y | 214 | 0.26 | 0.44 | 0 | 1 |
| Access | |||||
| 24 h to first visit | 430 | 0.53 | 0.50 | 0 | 1 |
| Diagnostic area | |||||
| Low back pain | 172 | 0.21 | 0.41 | 0 | 1 |
| Shoulder | 132 | 0.16 | 0.37 | 0 | 1 |
| Knee | 118 | 0.15 | 0.35 | 0 | 1 |
| Neck | 104 | 0.13 | 0.33 | 0 | 1 |
| Upper body, elbow, wrist, hand, or arm | 84 | 0.10 | 0.30 | 0 | 1 |
| Lower body, ankle, foot, or leg | 83 | 0.10 | 0.30 | 0 | 1 |
| Hip | 70 | 0.09 | 0.28 | 0 | 1 |
| Back or spine | 46 | 0.06 | 0.23 | 0 | 1 |
| Other | 5 | 0.01 | 0.08 | 0 | 1 |
Descriptive statistics for outcomes and predictors (N=814)
| Clinical baselines | Count | Mean | SD | Min | Max |
|---|---|---|---|---|---|
| Pain baseline (VAS) | 814 | 4.40 | 2.18 | 0 | 10 |
| Function baseline (PSFS) | 814 | 5.15 | 2.97 | 0 | 10 |
| Clinical outcomes | |||||
| Pain outcome (VAS) | 814 | 1.71 | 1.85 | 0 | 10 |
| Function outcome (PSFS) | 814 | 7.82 | 2.36 | 0 | 10 |
| Chronicity | |||||
| Chronic (>3 mo) | 497 | 0.61 | 0.49 | 0 | 1 |
| Subacute (1-3 mo) | 128 | 0.16 | 0.36 | 0 | 1 |
| Acute (<1 mo) | 189 | 0.23 | 0.42 | 0 | 1 |
| Baseline pain level categories | |||||
| Little to no pain (VAS≤1) | 61 | 0.07 | 0.26 | 0 | 1 |
| Mild pain (3.4≤VAS>1) | 218 | 0.27 | 0.44 | 0 | 1 |
| Moderate (7.4≤VAS>3.4) | 475 | 0.58 | 0.49 | 0 | 1 |
| Severe pain (VAS>7.4) | 60 | 0.07 | 0.26 | 0 | 1 |
| Comorbid conditions and adverse symptoms | |||||
| No. of comorbid conditions | 814 | 0.58 | 0.72 | 0 | 5 |
| Reported comorbid conditions | 383 | 0.47 | 0.50 | 0 | 1 |
| No. of adverse symptoms | 814 | 0.51 | 0.89 | 0 | 10 |
| Reported adverse symptoms | 281 | 0.35 | 0.48 | 0 | 1 |
Multilevel random intercept results (814 episodes, 1628 observations)
| Pain (VAS) | Coefficient | SE | 95% CI | ||
|---|---|---|---|---|---|
| Intercept | 3.78 | 0.10 | <.001 | (3.59 to | 3.97) |
| Treatment effect | −2.69 | 0.08 | <.001 | (−2.86 to | −2.53) |
| Female | 0.29 | 0.10 | .004 | (0.09 to | 0.49) |
| Comorbid conditions | 0.24 | 0.10 | .02 | (0.03 to | 0.44) |
| Adverse symptoms | 0.53 | 0.11 | <.001 | (0.32 to | 0.75) |
| Severe pain (VAS>7.4) | 2.57 | 0.19 | <.001 | (2.19 to | 2.95) |
| Random-effects variance | 0.63 | 0.09 | |||
| Unexplained model variance | 2.86 | ||||
| Function (PSFS) | |||||
| Intercept | 5.69 | 0.15 | <.001 | (5.40 to | 5.98) |
| Treatment effect | 2.67 | 0.11 | <.001 | (2.45 to | 2.89) |
| Comorbid conditions | −0.42 | 0.15 | .005 | (−0.72 to | −0.13) |
| Chronic condition (>3 mo) | −0.46 | 0.15 | .003 | (−0.76 to | −0.16) |
| Severe pain (VAS>7.4) | −0.92 | 0.29 | <.001 | (−1.48 to | −0.36) |
| Random-effects variance | 1.98 | 0.14 | |||
| Unexplained model variance | 5.10 | ||||